Form 4: Singular Genomics Systems Executive Exercises Stock Options
SEC Form 4 Filing
Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, Inc., reports the acquisition of 500 shares of common stock through the settlement of vested Restricted Stock Units.
Summary
- On August 9, 2024, Eli N. Glezer, the Chief Scientific Officer of Singular Genomics Systems, Inc., acquired 500 shares of common stock.
- This acquisition resulted from the settlement of vested Restricted Stock Units (RSUs).
- Each RSU represents the right to receive one share of the company's common stock.
- Following the transaction, Glezer directly owns 154,083 shares of Singular Genomics Systems, Inc.
- The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on June 26, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a change in insider ownership.
- Employees holding RSUs may be interested in the vesting schedule and settlement details.
Key Dates
| Date | Description |
|---|---|
| June 26, 2024 | Singular Genomics Systems effected a 1-for-30 reverse stock split of its common stock. |
| February 9, 2024 | The RSUs vest in 16 equal quarterly installments over four years measured from this date. |
| August 9, 2024 | Eli N. Glezer acquired 500 shares of common stock through RSU settlement. |
| August 13, 2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.